Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company, announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company, announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand via the conference portal starting at 7 a.m. ET on March 9. The management team will also host one-on-one investor meetings. Viracta focuses on treating virus-associated malignancies with its investigational drug, nanatinostat, currently in a Phase 2 trial for EBV-positive lymphoma.
Details
News Market Reaction – VIRX
The recorded move for VIRX in the trading session of this news was -4.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 3, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10, 2021. A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. Viracta's management team will also be available for one-on-one investor meetings at the conference.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact: | Company Contact: |
Joyce Allaire | Dan Chevallard |
LifeSci Advisors | Chief Financial Officer |
(212) 915-2569 | (858) 771-4193 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-participate-at-hc-wainwright-global-life-sciences-conference-301239433.html
SOURCE Viracta
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.